Opportunistic Protozoan Infections in Human
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Immunity Parasitic Infection
BLUE BOX RULES ARE FOR PROOF STAGE ONLY. DELETE BEFORE FINAL PRINTING. Editor LAMB IMMUNITY TO PARASITIC INFECTION PARASITIC IMMUNITY TO INFECTION Editor TRACEY J LAMB, Emory University School of Medicine, USA Parasitic infections remain a significant cause of morbidity and mortality in the world today. Often endemic in developing countries, many parasitic diseases are neglected in terms of research IMMUNITY funding and much remains to be understood about parasites and the interactions they have with the immune system. This book examines current knowledge about immune responses to parasitic TO infections affecting humans, including interactions that occur during co-infections, and how immune responses may be manipulated to develop therapeutic interventions against parasitic infection. For easy reference, the most commonly studied parasites are examined in individual chapters written by investigators at the forefront of their field. An overview of the immune system, as well as introductions PARASITIC to protozoan and helminth parasites, is included to guide background reading. A historical perspective of the field of immunoparasitology acknowledges the contributions of investigators who have been instrumental in developing this field of research. INFECTION • Written by investigators at the forefront of the field • Includes a glossary of terms for easy reference • Illustrated in full-colour throughout • Features separate sections on co-infection, applied parasitology and the development of vaccines against parasitic infections This book will be invaluable to advanced undergraduates and masters students as well as PhD students who are beginning their graduate research project in an area of immunoparasitology. A companion website with additional resources Editor TRACEY J LAMB is available at www.wiley.com/go/lamb/immunity Cover design by Dan Jubb Immunity to Parasitic Infection Immunity to Parasitic Infection Edited by Tracey J. -
(Sporanox Capsules) 280-A
PRIOR AUTHORIZATION CRITERIA BRAND NAME (generic) SPORANOX ORAL CAPSULES (itraconazole) Status: CVS Caremark Criteria Type: Initial Prior Authorization Policy FDA-APPROVED INDICATIONS Sporanox (itraconazole) Capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: 1. Blastomycosis, pulmonary and extrapulmonary 2. Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and 3. Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. Sporanox Capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: 1. Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and 2. Onychomycosis of the fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis. Compendial Uses Coccidioidomycosis2,3 -
Intestinal Protozoan Parasites in Northern India – Investigations on Transmission Routes
Intestinal protozoan parasites in Northern India – investigations on transmission routes Philosophiae Doctor (PhD) Thesis Kjersti Selstad Utaaker Department of Food Safety and Infection Biology Faculty of Veterinary Medicine Norwegian University of Life Sciences Adamstuen (2017) Thesis number 2018:10 ISSN 1894-6402 ISBN 978-82-575-1750-2 1 2 To Jenny, Vilmer, Viljar and Ivo. “India can do it. People of India can do it.” – PM Modi on Swachh Bharat Abhiyan 3 4 Contents Acknowledgements ................................................................................................................................. 7 Abbreviations ........................................................................................................................................ 10 List of research papers .......................................................................................................................... 12 List of additional papers ........................................................................................................................ 14 Summary ............................................................................................................................................... 15 Sammendrag (Norwegian summary) .................................................................................................... 18 सारा車श (Hindi summary) ......................................................................................................................... 21 1. Introduction .................................................................................................................................. -
HIV Infection and AIDS
G Maartens 12 HIV infection and AIDS Clinical examination in HIV disease 306 Prevention of opportunistic infections 323 Epidemiology 308 Preventing exposure 323 Global and regional epidemics 308 Chemoprophylaxis 323 Modes of transmission 308 Immunisation 324 Virology and immunology 309 Antiretroviral therapy 324 ART complications 325 Diagnosis and investigations 310 ART in special situations 326 Diagnosing HIV infection 310 Prevention of HIV 327 Viral load and CD4 counts 311 Clinical manifestations of HIV 311 Presenting problems in HIV infection 312 Lymphadenopathy 313 Weight loss 313 Fever 313 Mucocutaneous disease 314 Gastrointestinal disease 316 Hepatobiliary disease 317 Respiratory disease 318 Nervous system and eye disease 319 Rheumatological disease 321 Haematological abnormalities 322 Renal disease 322 Cardiac disease 322 HIV-related cancers 322 306 • HIV INFECTION AND AIDS Clinical examination in HIV disease 2 Oropharynx 34Neck Eyes Mucous membranes Lymph node enlargement Retina Tuberculosis Toxoplasmosis Lymphoma HIV retinopathy Kaposi’s sarcoma Progressive outer retinal Persistent generalised necrosis lymphadenopathy Parotidomegaly Oropharyngeal candidiasis Cytomegalovirus retinitis Cervical lymphadenopathy 3 Oral hairy leucoplakia 5 Central nervous system Herpes simplex Higher mental function Aphthous ulcers 4 HIV dementia Kaposi’s sarcoma Progressive multifocal leucoencephalopathy Teeth Focal signs 5 Toxoplasmosis Primary CNS lymphoma Neck stiffness Cryptococcal meningitis 2 Tuberculous meningitis Pneumococcal meningitis 6 -
Bacterial and Parasitic Infection of the Liver with Sebastian Lucas
Bacterial & parasitic infections Sebastian Lucas Dept of Histopathology St Thomas’ Hospital London SE1 Post-Tx infections Hepatitis A-x EBV HBV HCV Biliary tract infections HIV disease Crypto- sporidiosis CMV Other viral infections Bacterial & Parasitic infections Liver Hepatobiliary parasites • Leishmania spp • Trypanosoma cruzi • Entamoeba histolytica Biliary tree & GB • Toxoplasma gondii • microsporidia spp • Plasmodium falciparum • Balantidium coli • Cryptosporidium spp • Strongyloides stercoralis • Ascaris • Angiostrongylus spp • Fasciola hepatica • Enterobius vermicularis • Ascaris lumbricoides • Clonorchis sinensis • Baylisascaris • Opisthorcis viverrini • Toxocara canis • Dicrocoelium • Gnathostoma spp • Capillaria hepatica • Echinococcus granulosus • Schistosoma spp • Echinococcus granulosus & multilocularis Gutierrez: ‘Diagnostic Pathology of • pentasomes Parasitic Infections’, Oxford, 2000 What is this? Both are the same parasite What is this? Both are the same parasite Echinococcus multilocularis Bacterial infections of liver and biliary tree • Chlamydia trachomatis • Gram-ve rods • Treponema pallidum • Neisseria meningitidis • Borrelia spp • Yersina pestis • Leptospira spp • Streptococcus milleri • Mycobacterium spp • Salmonella spp – tuberculosis • Burkholderia pseudomallei – avium-intracellulare • Listeria monocytogenes – leprae • Brucella spp • Bartonella spp Actinomycetes • In ‘MacSween’ 2 manifestations of a classic bacterial infection Bacteria & parasites What you need to know 3 case studies • What can happen – differential -
PRIOR AUTHORIZATION CRITERIA BRAND NAME (Generic) SPORANOX ORAL CAPSULES (Itraconazole)
PRIOR AUTHORIZATION CRITERIA BRAND NAME (generic) SPORANOX ORAL CAPSULES (itraconazole) Status: CVS Caremark Criteria Type: Initial Prior Authorization Policy FDA-APPROVED INDICATIONS Sporanox (itraconazole) Capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: 1. Blastomycosis, pulmonary and extrapulmonary 2. Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and 3. Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. Sporanox Capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: 1. Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and 2. Onychomycosis of the fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis. Compendial Uses Coccidioidomycosis2,3 -
The Stem Cell Revolution Revealing Protozoan Parasites' Secrets And
Review The Stem Cell Revolution Revealing Protozoan Parasites’ Secrets and Paving the Way towards Vaccine Development Alena Pance The Wellcome Sanger Institute, Genome Campus, Hinxton Cambridgeshire CB10 1SA, UK; [email protected] Abstract: Protozoan infections are leading causes of morbidity and mortality in humans and some of the most important neglected diseases in the world. Despite relentless efforts devoted to vaccine and drug development, adequate tools to treat and prevent most of these diseases are still lacking. One of the greatest hurdles is the lack of understanding of host–parasite interactions. This gap in our knowledge comes from the fact that these parasites have complex life cycles, during which they infect a variety of specific cell types that are difficult to access or model in vitro. Even in those cases when host cells are readily available, these are generally terminally differentiated and difficult or impossible to manipulate genetically, which prevents assessing the role of human factors in these diseases. The advent of stem cell technology has opened exciting new possibilities to advance our knowledge in this field. The capacity to culture Embryonic Stem Cells, derive Induced Pluripotent Stem Cells from people and the development of protocols for differentiation into an ever-increasing variety of cell types and organoids, together with advances in genome editing, represent a huge resource to finally crack the mysteries protozoan parasites hold and unveil novel targets for prevention and treatment. Keywords: protozoan parasites; stem cells; induced pluripotent stem cells; organoids; vaccines; treatments Citation: Pance, A. The Stem Cell Revolution Revealing Protozoan 1. Introduction Parasites’ Secrets and Paving the Way towards Vaccine Development. -
Microsporidiosis in Vertebrate Companion Exotic Animals
Review Microsporidiosis in Vertebrate Companion Exotic Animals Claire Vergneau-Grosset 1,*,† and Sylvain Larrat 2,† Received: 13 October 2015; Accepted: 18 December 2015; Published: 24 December 2015 Academic Editor: Zhi-Yuan Chen 1 Zoological medicine service, Faculté de médecine vétérinaire, Université de Montréal, 3200 Sicotte, Saint-Hyacinthe, QC J2S2M2, Canada 2 Clinique Vétérinaire Benjamin Franklin, 38 rue du Danemark, ZA Porte Océane, 56400 Brech, France; [email protected] * Correspondence: [email protected]; Tel.: +1-450-773-8521 (ext. 16079) † These authors contributed equally to this work. Abstract: Veterinarians caring for companion animals may encounter microsporidia in various host species, and diagnosis and treatment of these fungal organisms can be particularly challenging. Fourteen microsporidial species have been reported to infect humans and some of them are zoonotic; however, to date, direct zoonotic transmission is difficult to document versus transit through the digestive tract. In this context, summarizing information available about microsporidiosis of companion exotic animals is relevant due to the proximity of these animals to their owners. Diagnostic modalities and therapeutic challenges are reviewed by taxa. Further studies are needed to better assess risks associated with animal microsporidia for immunosuppressed owners and to improve detection and treatment of infected companion animals. Keywords: microsporidia; Encephalitozoon; Pleistophora; albendazole; fenbendazole 1. Introduction Microsporidia are eukaryotic organisms with the smallest known genome [1]. Microsporidia had been classified as amitochondriate due to their lack of visible mitochondria, but sequences homologous to genes coding for mitochondria have since been discovered in their genome and remnants of mitochondria have been visualized in their cytoplasm [2]; therefore, they have been reclassified as fungi based on phylogenic analysis of multiple proteins in their genome, clustering preferentially with fungal proteins [2,3]. -
Transmission of Tropical and Geographically Restricted Infections During Solid-Organ Transplantation
CLINICAL MICROBIOLOGY REVIEWS, Jan. 2008, p. 60–96 Vol. 21, No. 1 0893-8512/08/$08.00ϩ0 doi:10.1128/CMR.00021-07 Copyright © 2008, American Society for Microbiology. All Rights Reserved. Transmission of Tropical and Geographically Restricted Infections during Solid-Organ Transplantation P. Martı´n-Da´vila,1,2* J. Fortu´n,1,2 R. Lo´pez-Ve´lez,1,3 F. Norman,3 M. Montes de Oca,3 P. Zamarro´n,3 M. I. Gonza´lez,3 A. Moreno,4 T. Pumarola,5 G. Garrido,6 A. Candela,7 and S. Moreno1 Infectious Diseases Department, Ramon y Cajal Hospital, Madrid, Spain1; Transplant Infectious Diseases Team, Ramon y Cajal Hospital, Madrid, Spain2; Tropical and Travel Medicine Unit, Ramon y Cajal Hospital, Madrid, Spain3; Infectious Diseases Department, Clinic Hospital, Barcelona, Spain4; Microbiology Department, Clinic Hospital, Barcelona, Spain5; Spanish Transplantation Network, Madrid, Spain6; and Anaesthesiology Department, Transplant Program, Ramon y Cajal Hospital, Madrid, Spain7 INTRODUCTION .........................................................................................................................................................62 Tropical and Geographically Restricted Infectious Diseases and Organ Transplantation ...........................62 VIRAL INFECTIONS...................................................................................................................................................63 Infections Caused by HTLV-1/2..............................................................................................................................63 -
A Possible Role for Fumagillin in Cellular Damage During Host
VIRULENCE 2018, VOL. 9, NO. 1, 1548–1561 https://doi.org/10.1080/21505594.2018.1526528 RESEARCH PAPER A possible role for fumagillin in cellular damage during host infection by Aspergillus fumigatus Xabier Guruceaga a, Guillermo Ezpeleta b,c, Emilio Mayayod, Monica Sueiro-Olivaresa, Ana Abad-Diaz-De- Cerio a, José Manuel Aguirre Urízar e, Hong G. Liuf,g, Philipp Wiemann h, Jin Woo Bokh, Scott G. Filler f,g, Nancy P. Keller h,i, Fernando L. Hernandoa, Andoni Ramirez-Garcia a, and Aitor Rementeria a aFungal and Bacterial Biomics Research Group, Department of Immunology, Microbiology and Parasitology, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), Leioa, Spain; bPreventive Medicine and Hospital Hygiene Service, Complejo Hospitalario de Navarra, Pamplona, Spain; cDepartment of Preventive Medicine and Public Health, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain; dPathology Unit, Medicine and Health Science Faculty, University of Rovira i Virgili, Reus, Tarragona, Spain; eDepartment of Stomatology II, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain; fDivision of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA; gDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; hDepartment of Medical Microbiology and Immunology, University of Wisconsin, Madison, WI, USA; iDepartment of Bacteriology, University of Wisconsin, Madison, WI, USA ABSTRACT ARTICLE HISTORY Virulence mechanisms of the pathogenic fungus Aspergillus fumigatus are multifactorial and Received 28 March 2018 depend on the immune state of the host, but little is known about the fungal mechanism that Accepted 10 September develops during the process of lung invasion. -
Protozoal-Related Mortalities in Endangered Hawaiian Monk Seals Neomonachus Schauinslandi
Vol. 121: 85–95, 2016 DISEASES OF AQUATIC ORGANISMS Published September 26 doi: 10.3354/dao03047 Dis Aquat Org Protozoal-related mortalities in endangered Hawaiian monk seals Neomonachus schauinslandi Michelle M. Barbieri1,*, Lizabeth Kashinsky2, David S. Rotstein3, Kathleen M. Colegrove4, Katherine H. Haman5,6,7, Spencer L. Magargal7, Amy R. Sweeny7, Angela C. Kaufman2, Michael E. Grigg7, Charles L. Littnan1 1National Oceanic and Atmospheric Administration, Pacific Islands Fisheries Science Center, Protected Species Division, Hawaiian Monk Seal Research Program, Honolulu, HI 96818, USA 2Joint Institute for Marine and Atmospheric Research, University of Hawai’i at Ma¯ noa, 1000 Pope Road, Marine Sciences Building 312, Honolulu, HI 96822 USA 3Marine Mammal Pathology Services, Olney, MD 20832, USA 4Zoological Pathology Program, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Brookfield, IL 60513, USA 5Health and Genetics Program, Washington Department of Fish and Wildlife, Olympia, WA 98501, USA 6Marine Mammal Research Unit, Institute for the Oceans and Fisheries, University of British Columbia, Vancouver, V6T 1Z4, BC, Canada 7Molecular Parasitology Section, Laboratory of Parasitic Diseases, NIAID, National Institutes of Health, Bethesda, MD 20892, USA ABSTRACT: Protozoal infections have been widely documented in marine mammals and may cause morbidity and mortality at levels that result in population level effects. The presence and potential impact on the recovery of endangered Hawaiian monk seals Neomonachus schauins- landi by protozoal pathogens was first identified in the carcass of a stranded adult male with dis- seminated toxoplasmosis and a captive monk seal with hepatitis. We report 7 additional cases and 2 suspect cases of protozoal-related mortality in Hawaiian monk seals between 2001 and 2015, including the first record of vertical transmission in this species. -
Predominance of Blastocystis Sp. Infection Among School Children in Peninsular Malaysia
RESEARCH ARTICLE Predominance of Blastocystis sp. Infection among School Children in Peninsular Malaysia Kalimuthu Nithyamathi1, Samudi Chandramathi2, Suresh Kumar1* 1 Department of Parasitology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, 2 Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia * [email protected] a11111 Abstract Background One of the largest cross-sectional study in recent years was carried out to investigate the prevalence of intestinal parasitic infections among urban and rural school children from five OPEN ACCESS states namely Selangor, Perak, Pahang, Kedah and Johor in Peninsula Malaysia. This Citation: Nithyamathi K, Chandramathi S, Kumar S information would be vital for school authorities to influence strategies for providing better (2016) Predominance of Blastocystis sp. Infection health especially in terms of reducing intestinal parasitism. among School Children in Peninsular Malaysia. PLoS ONE 11(2): e0136709. doi:10.1371/journal. pone.0136709 Methods and Principal Findings Editor: Henk D. F. H. Schallig, Royal Tropical A total of 3776 stool cups was distributed to 26 schools throughout the country. 1760 Institute, NETHERLANDS (46.61%) responded. The overall prevalence of intestinal parasitic infection in both rural and Received: August 12, 2014 urban areas was 13.3%, with Blastocystis sp (10.6%) being the most predominant, followed Accepted: August 8, 2015 by Trichuris trichiura (3.4%), Ascaris lumbricoides (1.5%) and hook worm infection (0.9%). Published: February 25, 2016 Only rural school children had helminthic infection. In general Perak had the highest infec- tion (37.2%, total, n = 317), followed by Selangor (10.4%, total, n = 729), Pahang (8.6%, Copyright: © 2016 Nithyamathi et al.